search
Back to results

Treatment Trial for Post-Thrombotic Syndrome

Primary Purpose

Post Thrombotic Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
complex lymphedema therapy
Sponsored by
University of Vermont
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post Thrombotic Syndrome focused on measuring Post thrombotic syndrome, Thrombosis, Deep vein thrombosis, Venous thrombosis, Edema, stasis ulcers

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age >18 years.
  • Diagnosis of post thrombotic syndrome.
  • Median life expectancy of greater than 2 years.
  • Previous history of lower extremity deep venous thrombosis.

Exclusion Criteria:

  • Acute venous thrombosis of the lower extremity within the last 180 days.
  • Unable to participate in lymphedema therapy due to monetary, physical or transportation limitations.
  • Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women and women in their first post-partum month.

Sites / Locations

  • Fletcher Allen Health Care; Department of Hematology/Oncology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

A

B

Arm Description

Complex lymphedema therapy (which includes compression stocking use)

Standard of care (compression stocking use at 30-40 mm Hg)

Outcomes

Primary Outcome Measures

To determine if complex lymphedema therapy improves the quality of life in patients with post-thrombotic syndrome
To determine if complex lymphedema therapy reduces disease severity in patients with post thrombotic syndrome

Secondary Outcome Measures

To assess side effects of lymphedema therapy when administered to patients with PTS
To determine if selected biomarkers correlate with disease severity and response to lymphedema therapy in patients with post thrombotic syndrome

Full Information

First Posted
March 4, 2008
Last Updated
September 15, 2020
Sponsor
University of Vermont
search

1. Study Identification

Unique Protocol Identification Number
NCT00633971
Brief Title
Treatment Trial for Post-Thrombotic Syndrome
Official Title
A Randomized Trial to Determine the Impact of Lymphedema Therapy on Quality of Life and Disease Severity in Patients With Post-Thrombotic Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
June 2010 (Actual)
Study Completion Date
September 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if complex lymphedema therapy is effective in decreasing disease severity and improving quality of life in patients with post thrombotic syndrome.
Detailed Description
Post thrombotic syndrome (PTS) has a spectrum of disease manifestations ranging from minor skin discoloration to severe skin changes and venous ulcerations. Pain is often a prominent symptoms and PTS impairs patient quality of life. Prevention of PTS using compression stockings has been emphasized. There is a paucity of validated, effective treatments for PTS once the condition develops. While the pathophysiology of PTS is incompletely understood, chronic venous hypertension and insufficiency may increase the workload of the lymphatic system and result in over-capacitance with secondary damage and eventual lymphatic insufficiency. In selected patients with PTS, we have noted a symptomatic improvement in patients who receive lymphedema therapy to the limb. Complex lymphedema therapy (CLT) is a noninvasive treatment that includes four key components: meticulous skin care, manual lymph drainage, compression therapy, exercises and patient education for home management and continuation of the treatment. These techniques are designed to enhance lymph flow through intact cutaneous lymphatics and reduce swelling and restore function in the affected limb.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Thrombotic Syndrome
Keywords
Post thrombotic syndrome, Thrombosis, Deep vein thrombosis, Venous thrombosis, Edema, stasis ulcers

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
Complex lymphedema therapy (which includes compression stocking use)
Arm Title
B
Arm Type
Other
Arm Description
Standard of care (compression stocking use at 30-40 mm Hg)
Intervention Type
Other
Intervention Name(s)
complex lymphedema therapy
Intervention Description
Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
Primary Outcome Measure Information:
Title
To determine if complex lymphedema therapy improves the quality of life in patients with post-thrombotic syndrome
Time Frame
1 and 3 months
Title
To determine if complex lymphedema therapy reduces disease severity in patients with post thrombotic syndrome
Time Frame
1 and 3 months
Secondary Outcome Measure Information:
Title
To assess side effects of lymphedema therapy when administered to patients with PTS
Time Frame
1 and 3 months
Title
To determine if selected biomarkers correlate with disease severity and response to lymphedema therapy in patients with post thrombotic syndrome
Time Frame
1 and 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age >18 years. Diagnosis of post thrombotic syndrome. Median life expectancy of greater than 2 years. Previous history of lower extremity deep venous thrombosis. Exclusion Criteria: Acute venous thrombosis of the lower extremity within the last 180 days. Unable to participate in lymphedema therapy due to monetary, physical or transportation limitations. Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant women and women in their first post-partum month.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chris E Holmes, MD, PhD
Organizational Affiliation
University of Vermont and Fletcher Allen Health Care
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fletcher Allen Health Care; Department of Hematology/Oncology
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
24558028
Citation
Holmes CE, Bambace NM, Lewis P, Callas PW, Cushman M. Efficacy of a short course of complex lymphedema therapy or graduated compression stocking therapy in the treatment of post-thrombotic syndrome. Vasc Med. 2014 Feb;19(1):42-8. doi: 10.1177/1358863X14521883.
Results Reference
derived
Links:
URL
http://www.vermontcancer.org
Description
Dedicated to improving the human condition affected by cancer, through research in the laboratory and in the clinic, cancer prevention and control research and programs, state-of-the art cancer diagnosis.

Learn more about this trial

Treatment Trial for Post-Thrombotic Syndrome

We'll reach out to this number within 24 hrs